Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiffany Tang

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2014
HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 responseBarak Rotblat, Amber L Southwell, Dagmar E Ehrnhoefer, et al.
Cell Reports. Medicine|September 20, 2023
A blood-based metabolomic signature predictive of risk for pancreatic cancerEhsan Irajizad, Ana Kenney, Tiffany Tang, et al.
Cancer Reports (Hoboken, N.J.)|April 28, 2022
Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapyTricia Tay, Nagavalli Somasundaram, Cindy Lim, et al.
Cancer Discovery|June 19, 2012
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphomaGhee Chong Koo, Soo Yong Tan, Tiffany Tang, et al.
Therapeutic Advances in Medical Oncology|April 18, 2022
A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignanciesJingshan Ho, Valerie Heong, Wei Peng Yong, et al.
Blood Cancer Journal|November 14, 2018
Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphomaJason Yongsheng Chan, Alvin Yu Jin Ng, Chee Leong Cheng, et al.
Blood Cancer Journal|January 29, 2020
Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphomaSanjay de Mel, Masturah B M Rashid, Xi Yun Zhang, et al.
Blood|July 29, 2018
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphomaTammy Linlin Song, Maarja-Liisa Nairismägi, Yurike Laurensia, et al.
Science Translational Medicine|October 19, 2022
An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphomaJasmine Goh, Sanjay De Mel, Michal M Hoppe, et al.
Cancer Discovery|April 18, 2023
Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in LymphomaMichal Marek Hoppe, Patrick Jaynes, Fan Shuangyi, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Proceedings of the National Academy of Sciences of the United States of America|February 12, 2014
HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 responseBarak Rotblat, Amber L Southwell, Dagmar E Ehrnhoefer, et al.
Cell Reports. Medicine|September 20, 2023
A blood-based metabolomic signature predictive of risk for pancreatic cancerEhsan Irajizad, Ana Kenney, Tiffany Tang, et al.
Cancer Reports (Hoboken, N.J.)|April 28, 2022
Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapyTricia Tay, Nagavalli Somasundaram, Cindy Lim, et al.
Cancer Discovery|June 19, 2012
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphomaGhee Chong Koo, Soo Yong Tan, Tiffany Tang, et al.
Therapeutic Advances in Medical Oncology|April 18, 2022
A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignanciesJingshan Ho, Valerie Heong, Wei Peng Yong, et al.
Blood Cancer Journal|November 14, 2018
Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphomaJason Yongsheng Chan, Alvin Yu Jin Ng, Chee Leong Cheng, et al.
Blood Cancer Journal|January 29, 2020
Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphomaSanjay de Mel, Masturah B M Rashid, Xi Yun Zhang, et al.
Blood|July 29, 2018
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphomaTammy Linlin Song, Maarja-Liisa Nairismägi, Yurike Laurensia, et al.
Science Translational Medicine|October 19, 2022
An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphomaJasmine Goh, Sanjay De Mel, Michal M Hoppe, et al.
Cancer Discovery|April 18, 2023
Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in LymphomaMichal Marek Hoppe, Patrick Jaynes, Fan Shuangyi, et al.
Pageof 10